Acute Liver Injury during Co-treatment with Levetiracetam and Temozolomide
Journal Title: Liver Research – Open Journal - Year 2015, Vol 1, Issue 1
Abstract
Drug-induced liver injury (DILI) accounts for approximately 10 percent of all cases of acute hepatitis. The patterns of acute injury include any form of hepatic injury, but the most common problems are cholestasis, hepatocellular damage, or a mixed type. DILI is often reversible, and discontinuation of the offending agent usually results in a complete recovery; however, some cases may lead to chronic liver injury, cirrhosis, and even death. Temozolomide (TMZ) is an alkylating, anti-neoplastic agent used for the treatment of refractory anaplastic astrocytoma, newly-diagnosed Glioblastoma multiforme (GBM) and metastatic melanoma. Levetiracetam (LEV) is an established second-generation antiepileptic drug and is most commonly approved as adjunctive treatment of partial-onset seizures with or without secondary generalization. When administered separately each of these drugs is considered to be relatively safe and only few cases of severe liver injury can be found throughout the literature; however, LEV and TMZ are commonly used together in the treatment of brain malignancies. We report three patients who presented with jaundice during treatment with TMZ and LEV, and propose a mechanism for liver sensitization by LEV for TMZ-induced injury.
Authors and Affiliations
Meir Mizrahi
Keywords
Related Articles
- EP ID EP556445
- DOI 10.17140/LROJ-1-104
- Views 137
- Downloads 0
Magnetic Resonance Elastography Comes of Age
Clinicians are always in search of a less invasive method of diagnosing and assessing a patient. Patients with liver cirrhosis are no exception. Liver cirrhosis is the end stage of many liver pathologies and knowledge of...
“Cardiac Hepatopathy”: A Review of Liver Dysfunction in Heart Failure
The unique dual circulation of the liver confers relative protection against ischemic injury; however, low oxygen tension in the microcirculation (sinusoidal blood of the hepatic acinus) may render hepatocytes in zone 3...
Comparisons between Portosystemic Shunting Modalities in Patients with Liver Cirrhosis and Portal Hypertension
During almost half of century period, in the Department of Surgery of Portal Hypertension and Pancreatoduodenal Zone of the JSC “Republican Specialized Center of Surgery (named after Academician V. Vakhidov”), portosyste...
Targeted Therapy for Hepatocellular Carcinoma: What`s New?
Hepatocellular carcinoma (HCC), one of the most frequent neoplasms worldwide, causes more than 700,000 deaths per year, and is the third cause of cancer-related mortality.1-3 HCC occurs after years of damage to hepatocyt...
Hepatitis C Update
The pace of Hepatitis C Virus (HCV) drug development in recent years has accelerated dramatically. But, for patients to benefit from these impressive advances, practitioners (i.e. “us”) need to know the most recent and a...